Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.

[1]  C. Viboud,et al.  Explorer The genomic and epidemiological dynamics of human influenza A virus , 2016 .

[2]  Yugo Shobugawa,et al.  Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006-2007 influenza season in Japan. , 2008, The Journal of infectious diseases.

[3]  R. Garten,et al.  Reply to Saito et al. , 2008 .

[4]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[5]  C. Rayner,et al.  A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination , 2007, PloS one.

[6]  Phillip Andrew Reece,et al.  Neuraminidase inhibitor resistance in influenza viruses , 2007, Journal of medical virology.

[7]  Mark A. Miller,et al.  The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. , 2007, Molecular biology and evolution.

[8]  I. Barr,et al.  The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. , 2007, Antiviral research.

[9]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[10]  T. Finsterbusch,et al.  Low Dose Oral Combination Chemoprophylaxis with Oseltamivir and Amantadine for Influenza a Virus Infections in Mice , 2007, Journal of chemotherapy.

[11]  I. Barr,et al.  Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. , 2007, Antiviral research.

[12]  A. Hatzakis,et al.  Role of combination antiviral therapy in pandemic influenza and stockpiling implications , 2007, BMJ : British Medical Journal.

[13]  I. Barr,et al.  Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. , 2007, Antiviral research.

[14]  A. Galabov,et al.  Rimantadine and Oseltamivir Demonstrate Synergistic Combination Effect in an Experimental Infection with Type a (H3N2) Influenza Virus in Mice , 2006, Antiviral chemistry & chemotherapy.

[15]  R. Webster,et al.  Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. , 2006, Antiviral research.

[16]  Gavin J. D. Smith,et al.  Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. , 2006, The Journal of infectious diseases.

[17]  R. Webster,et al.  Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice , 2006, Antiviral therapy.

[18]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[19]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[20]  G. Boivin,et al.  Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations , 2005, Antimicrobial Agents and Chemotherapy.

[21]  Sudhir Kumar,et al.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment , 2004, Briefings Bioinform..

[22]  I. Arkin,et al.  A novel method of resistance for influenza against a channel‐blocking antiviral drug , 2004, Proteins.

[23]  I. Barr,et al.  Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. , 2004, Antiviral research.

[24]  I. Barr,et al.  Reassortants in recent human influenza A and B isolates from South East Asia and Oceania. , 2003, Virus research.

[25]  H. Goto,et al.  High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. , 2003, The Journal of infectious diseases.

[26]  G L Ada,et al.  Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). , 1997, Vaccine.

[27]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[28]  J. Skehel,et al.  Molecular basis of resistance of influenza A viruses to amantadine. , 1986, The Journal of antimicrobial chemotherapy.

[29]  J. Skehel,et al.  The molecular basis of the specific anti‐influenza action of amantadine. , 1985, The EMBO journal.

[30]  I. Barr,et al.  Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. , 2006, Communicable diseases intelligence quarterly report.

[31]  Atlanta,et al.  Morbidity and Mortality Weekly Report Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices (acip) Editorial and Production Staff Lead Technical Writer-editor Project Editor Recommendations for Using Antiviral Agents for Influenza . 24 Indications fo , 2022 .